| The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort CH Williams-Gray, SL Mason, JR Evans, T Foltynie, C Brayne, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1258-1264, 2013 | 731 | 2013 |
| Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial S Palfi, JM Gurruchaga, GS Ralph, H Lepetit, S Lavisse, PC Buttery, ... The Lancet 383 (9923), 1138-1146, 2014 | 530 | 2014 |
| CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ... Neurology 78 (10), 690-695, 2012 | 441 | 2012 |
| Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease RA Barker, J Barrett, SL Mason, A Björklund The Lancet Neurology 12 (1), 84-91, 2013 | 432 | 2013 |
| Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort SE Winder-Rhodes, JR Evans, M Ban, SL Mason, CH Williams-Gray, ... Brain 136 (2), 392-399, 2013 | 344 | 2013 |
| Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ... The Lancet Neurology 16 (9), 701-711, 2017 | 317 | 2017 |
| Cerebrovascular and blood-brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology. CF Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagacé M, Kuan WL, Saint-Pierre M ... Annals of Neurology, 2015 | 288 | 2015 |
| The natural history of treated Parkinson's disease in an incident, community based cohort JR Evans, SL Mason, CH Williams-Gray, T Foltynie, C Brayne, ... Journal of Neurology, Neurosurgery & Psychiatry 82 (10), 1112-1118, 2011 | 283 | 2011 |
| Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's G Liu, B Boot, JJ Locascio, IE Jansen, S Winder‐Rhodes, S Eberly, ... Annals of neurology 80 (5), 674-685, 2016 | 267 | 2016 |
| The Cambridge behavioural inventory revised HJ Wear, CJ Wedderburn, E Mioshi, CH Williams-Gray, SL Mason, ... Dementia & neuropsychologia 2, 102-107, 2008 | 244 | 2008 |
| Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study M Politis, N Pavese, YF Tai, L Kiferle, SL Mason, DJ Brooks, SJ Tabrizi, ... Human brain mapping 32 (2), 258-270, 2011 | 243 | 2011 |
| Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study JS Paulsen, JD Long, HJ Johnson, EH Aylward, CA Ross, JK Williams, ... Frontiers in aging neuroscience 6, 78, 2014 | 234 | 2014 |
| Health‐related quality of life in Huntington's disease: which factors matter most? AK Ho, AS Gilbert, SL Mason, AO Goodman, RA Barker Movement Disorders 24 (4), 574-578, 2009 | 203 | 2009 |
| The utility of the Cambridge Behavioural Inventory in neurodegenerative disease C Wedderburn, H Wear, J Brown, SJ Mason, RA Barker, J Hodges, ... Journal of Neurology, Neurosurgery & Psychiatry 79 (5), 500-503, 2008 | 203 | 2008 |
| Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT‐HD study KM Biglan, CA Ross, DR Langbehn, EH Aylward, JC Stout, S Queller, ... Movement Disorders 24 (12), 1763-1772, 2009 | 185 | 2009 |
| Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts G Liu, JJ Locascio, JC Corvol, B Boot, Z Liao, K Page, D Franco, K Burke, ... The Lancet Neurology 16 (8), 620-629, 2017 | 162 | 2017 |
| A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease Huntington Study Group HART Investigators Movement Disorders 28 (10), 1407-1415, 2013 | 153 | 2013 |
| Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington’s disease I Reuter, YF Tai, N Pavese, KR Chaudhuri, S Mason, CE Polkey, ... Journal of Neurology, Neurosurgery & Psychiatry 79 (8), 948-951, 2008 | 143 | 2008 |
| Long-term follow-up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease S Palfi, JM Gurruchaga, H Lepetit, K Howard, GS Ralph, S Mason, ... Human Gene Therapy Clinical Development 29 (3), 148-155, 2018 | 137 | 2018 |
| Alteration of blood–brain barrier integrity by retroviral infection PV Afonso, S Ozden, MC Cumont, D Seilhean, L Cartier, P Rezaie, ... PLoS pathogens 4 (11), e1000205, 2008 | 135 | 2008 |
Roger A BarkerUniversity of CambridgeVerified email at cam.ac.uk
